NWAM LLC’s Inovio Pharmaceuticals INO Stock Holding History

NWAM LLC’s Portfolio INO Stock Details INO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-1,333	Closed	-$57K	–	532
2022 Q1	$57K	Hold	1,333	–	–	﹤0.01%	520
2021 Q4	$80K	Hold	1,333	–	–	0.01%	501
2021 Q3	$115K	Sell	1,333 -17	-1%	-$1.71K	0.01%	482
2021 Q2	$150K	Buy	1,350 +42	+3%	+$4.03K	0.01%	458
2021 Q1	$146K	Buy	1,308 +58	+5%	+$7.63K	0.01%	471
2020 Q4	$133K	Buy	1,250 +417	+50%	+$55.5K	0.02%	441
2020 Q3	$116K	Sell	833 -9	-1%	-$1.88K	0.02%	230
2020 Q2	$272K	Buy	+842	New	+$135K	0.04%	334

Other funds holding INO

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Rafferty Asset Management New York $24.6B AUM 47.06% 1-Year Est. Return

NWAM LLC's INO Position: Q2 2022 in Review

NWAM LLC sold out of Inovio Pharmaceuticals (INO) in Q2 2022, closing a stake of 1,333 shares — an estimated $57K sold.

NWAM LLC first reported a position in INO in Q2 2020 and held it in 8 quarters. The position peaked at $272K in Q2 2020. 184 funds tracked by Wall St. Rank hold INO as of Q2 2022.

NWAM LLC reported no remaining Inovio Pharmaceuticals position as of Q2 2022 after selling out during the quarter.
NWAM LLC sold 1,333 Inovio Pharmaceuticals shares in Q2 2022, an estimated $57K.
NWAM LLC first reported a position in Inovio Pharmaceuticals in Q2 2020 and held it in 8 quarters.
NWAM LLC's Inovio Pharmaceuticals position peaked at $272K in Q2 2020.
184 funds tracked by Wall St. Rank held Inovio Pharmaceuticals as of Q2 2022.

Based on NWAM LLC's 13F filing for Q2 2022, filed 10 Aug 2022.